当前位置: X-MOL 学术Drug. Discov. Today › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Thymoquinone-based nanotechnology for cancer therapy: promises and challenges
Drug Discovery Today ( IF 7.4 ) Pub Date : 2018-01-31 , DOI: 10.1016/j.drudis.2018.01.043
Farah Ballout , Zeina Habli , Omar Nasser Rahal , Maamoun Fatfat , Hala Gali-Muhtasib

Thymoquinone (TQ), the active ingredient of black seed, is a promising anticancer molecule that inhibits cancer cell growth and progression in vitro and in vivo. Despite the promising anticancer activities of TQ, its translation to the clinic is limited by its poor bioavailability and hydrophobicity. As such, we and others encapsulated TQ in nanoparticles to improve its delivery and limit undesirable cytotoxicity. These TQ-nanoparticle formulations showed improved anticancer and anti-inflammatory activities when compared with free TQ. Here, we provide an overview of the various TQ-nanoparticle formulations, highlight their superior efficacy and discuss up-to-date solutions to further enhance TQ bioavailability and anticancer activity, thus improving potential for clinical translation.



中文翻译:

基于胸腺醌的纳米技术在癌症治疗中的前景与挑战

胸腺素(TQ)是黑种子的活性成分,是一种有前途的抗癌分子,可在体外体内抑制癌细胞的生长和进程尽管TQ具有良好的抗癌活性,但由于其生物利用度和疏水性差,其在临床上的应用受到限制。因此,我们和其他人将TQ封装在纳米颗粒中,以改善其传递并限制不良的细胞毒性。与游离TQ相比,这些TQ纳米颗粒制剂显示出改善的抗癌和抗炎活性。在这里,我们提供了各种TQ纳米颗粒制剂的概述,着重介绍了其卓越的功效,并讨论了最新的解决方案,以进一步增强TQ的生物利用度和抗癌活性,从而提高了临床翻译的潜力。

更新日期:2018-01-31
down
wechat
bug